Summit Therapeutics Inc (NASDAQ:SMMT) has a beta value of -0.46 and has seen 0.72 million shares traded in the recent trading session. The company, currently valued at $14.44B, closed the recent trade at $19.58 per share which meant it gained $0.29 on the day or 1.50% during that session. The SMMT stock price is -73.08% off its 52-week high price of $33.89 and 89.27% above the 52-week low of $2.10. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.02 million shares traded. The 3-month trading volume is 2.45 million shares.
The consensus among analysts is that Summit Therapeutics Inc (SMMT) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.07.
Summit Therapeutics Inc (NASDAQ:SMMT) trade information
Sporting 1.50% in the green today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the SMMT stock price touched $19.58 or saw a rise of 9.77%. Year-to-date, Summit Therapeutics Inc shares have moved 9.72%, while the 5-day performance has seen it change -3.26%. Over the past 30 days, the shares of Summit Therapeutics Inc (NASDAQ:SMMT) have changed 2.35%. Short interest in the company has seen 21.22 million shares shorted with days to cover at 7.34.
Wall Street analysts have a consensus price target for the stock at $37, which means that the shares’ value could jump 47.08% from the levels at last check today. The projected low price target is $32.0 while the price target rests at a high of $42.0. In that case, then, we find that the latest price level in today’s session is -114.5% off the targeted high while a plunge would see the stock gain -63.43% from the levels at last check today.
Summit Therapeutics Inc (SMMT) estimates and forecasts
The company’s shares have lost -6.25% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -10.52% over the past 5 years. Earnings growth for 2025 is a modest -38.33% while over the next 5 years, the company’s earnings are expected to decrease by -27.50%.
SMMT Dividends
Summit Therapeutics Inc is expected to release its next earnings report on 2025-Feb-23 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Summit Therapeutics Inc (NASDAQ:SMMT)’s Major holders
Insiders own 84.36% of the company shares, while shares held by institutions stand at 12.91% with a share float percentage of 82.56%. Investors are also buoyed by the number of investors in a company, with Summit Therapeutics Inc having a total of 273.0 institutions that hold shares in the company. The top two institutional holders are BAKER BROS. ADVISORS LP with over 23.22 million shares worth more than $181.13 million. As of 2024-06-30, BAKER BROS. ADVISORS LP held 3.2804% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 8.82 million shares as of 2024-06-30. The firm’s total holdings are worth over $68.78 million and represent 1.2566% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF. As of Dec 31, 2024, the former fund manager holds about 0.46% shares in the company for having 3.4 shares of worth $67.69 million while later fund manager owns 3.32 shares of worth $66.01 million as of Feb 28, 2025, which makes it owner of about 0.45% of company’s outstanding stock.
